Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$191.51 - $216.16 $1,723 - $1,945
9 Added 0.28%
3,273 $694,000
Q2 2023

Aug 14, 2023

BUY
$187.64 - $206.25 $126,094 - $138,600
672 Added 25.93%
3,264 $628,000
Q1 2023

May 15, 2023

SELL
$127.59 - $203.08 $20,924 - $33,305
-164 Reduced 5.95%
2,592 $524,000
Q4 2022

Feb 08, 2023

SELL
$117.37 - $139.17 $23,943 - $28,390
-204 Reduced 6.89%
2,756 $354,000
Q3 2022

Nov 15, 2022

SELL
$135.27 - $180.11 $133,782 - $178,128
-989 Reduced 25.04%
2,960 $405,000
Q2 2022

Aug 10, 2022

BUY
$108.81 - $179.33 $89,441 - $147,409
822 Added 26.29%
3,949 $699,000
Q1 2022

May 10, 2022

SELL
$119.61 - $157.85 $10,406 - $13,732
-87 Reduced 2.71%
3,127 $450,000
Q4 2021

Feb 04, 2022

SELL
$142.57 - $190.86 $26,803 - $35,881
-188 Reduced 5.53%
3,214 $497,000
Q3 2021

Nov 10, 2021

BUY
$142.45 - $169.82 $220,939 - $263,390
1,551 Added 83.79%
3,402 $578,000
Q2 2021

Aug 10, 2021

SELL
$135.08 - $161.1 $1.09 Million - $1.3 Million
-8,051 Reduced 81.31%
1,851 $292,000
Q1 2021

May 11, 2021

BUY
$137.51 - $190.8 $1.1 Million - $1.53 Million
7,997 Added 419.79%
9,902 $1.38 Million
Q4 2020

Feb 12, 2021

BUY
$164.63 - $211.93 $313,620 - $403,726
1,905 New
1,905 $334,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.